Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

December 12, 2021

Primary Completion Date

February 6, 2024

Study Completion Date

February 28, 2024

Conditions
Asthma
Interventions
DRUG

Rilzabrutinib

Pharmaceutical form: Tablet Route of administration: Oral

DRUG

placebo

Pharmaceutical form: Tablet Route of administration: Oral

Trial Locations (51)

1612

Investigational Site Number : 1000002, Sofia

3320

Investigational Site Number : 1000004, Kozloduy

3780

Investigational Site Number : 3480001, Edelény

4080

Investigational Site Number : 3480004, Hajdunánás

5400

Investigational Site Number : 1000003, Sevlievo

7002

Investigational Site Number : 1000001, Rousse

7635

Investigational Site Number : 3480003, Pécs

15010

Investigational Site Number : 6160005, Bialystok

28007

Investigational Site Number : 7240003, Madrid / Madrid

29010

Investigational Site Number : 7240001, Málaga

33070

Investigational Site Number : 7920001, Mersin

34000

Investigational Site Number : 4840003, Durango

34303

Investigational Site Number : 7920002, Istanbul

39008

Investigational Site Number : 7240004, Santander

40225

Investigational Site Number : 6420001, Düsseldorf

44100

Investigational Site Number : 4840001, Guadalajara

64460

Investigational Site Number : 4840002, Monterrey

76800

Investigational Site Number : 4840005, San Juan del Río

90141

Investigational Site Number : 6160001, Lodz

91910

Investigational Site Number : 4840004, Veracruz

400012

Investigational Site Number : 6420002, Cluj-Napoca

2260877

Investigational Site Number : 1520006, Quillota

3341643

Investigational Site Number : 1520005, Curicó

7500692

Investigational Site Number : 1520001, Santiago

7500698

Investigational Site Number : 1520004, Santiago

8241470

Investigational Site Number : 1520007, Santaigo

8910131

Investigational Site Number : 1520003, Santiago

CP 1884

Investigational Site Number : 0320004, Berazategui

C1122AAK

Investigational Site Number : 0320006, CABA

C1425FVH

Investigational Site Number : 0320003, CABA

C1121ABE

Investigational Site Number : 0320001, Buenos Aires

C1414AIF

Investigational Site Number : 0320005, Ciudad Autonoma Buenos Aires

C1425BEN

Investigational Site Number : 0320002, Ciudad Autonoma Buenos Aires

V5Z 1M9

Investigational Site Number : 1240006, Vancouver

N2J 1C4

Investigational Site Number : 1240005, Waterloo

Unknown

Investigational Site Number : 1520002, Talca

61-578

Investigational Site Number : 6160009, Poznan

20-362

Investigational Site Number : 6160007, Lublin

15-044

Investigational Site Number : 6160003, Bialystok

80-214

Investigational Site Number : 6160006, Gdansk

30-033

Investigational Site Number : 6160002, Krakow

90-752

Investigational Site Number : 6160010, Lodz

27-400

Investigational Site Number : 6160008, Ostrowiec Świętokrzyski

705-717

Investigational Site Number : 4100007, Daegu

03312

Investigational Site Number : 4100004, Seoul

05030

Investigational Site Number : 4100005, Seoul

05505

Investigational Site Number : 4100002, Seoul

08308

Investigational Site Number : 4100006, Seoul

06591

Investigational Site Number : 4100001, Seoul

CB2 OQQ

Investigational Site Number : 8260002, Cambridge

BD9 6RJ

Investigational Site Number : 8260001, Bradford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY